ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2098

Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study

Ehizogie Edigin1, Amy Trang2, Chinenye Osuorji3, Christopher Hino1, Solomon Anighoro4, Precious Eseaton5, Nneka Chukwu6, Osaigbokan Aihie7, Augustine Manadan2 and vaneet Sandhu8, 1Loma Linda University Health, Loma Linda, CA, 2Rush University Medical Center, Chicago, IL, 3Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, 4St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, 5University of South Wales, Cardiff, Wales, United Kingdom, 6Nuvance Health, Poughkeepsie, 7University of Missouri, St. Loius, MO, 8Loma Linda University, Loma Linda, CA

Meeting: ACR Convergence 2022

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Lupus can present as either systemic lupus erythematous (SLE) and/or a cutaneous form known as cutaneous lupus erythematous (CLE). While a lot of data exists on SLE hospitalization, large population studies on CLE hospitalizations are limited. We aim to determine the most common reasons for hospitalization of patients with CLE. We also aim to compare baseline demographic and hospital outcomes of hospitalizations of patients with CLE (without any systemic manifestations) and patients with SLE with organ involvement.

Methods: The National Inpatient Sample (NIS) is the largest inpatient all-payer public database in the United States (US). We obtained data from the NIS 2016-2019 databases. For the CLE cohort, we abstracted data for patients aged ≥18 years with any diagnosis of CLE, using the ICD-10 code “L93”. CLE cohort includes patients with discoid lupus erythematosus, subacute cutaneous lupus erythematosus, lupus erythematosus profundus, and lupus panniculitis. We excluded patients with any form of SLE using ICD-10 code “M32” from the CLE cohort. For comparison, we obtained the SLE cohort by searching for patients aged ≥18 years with any diagnosis of SLE with organ involvement using ICD-10 code “M321”. Analyses were performed using STATA, version 16. By using a “rank” command in STATA, the most common principal discharge diagnoses were divided into categories based on organ system, and the most common specific principal discharge diagnoses were recorded for the CLE cohort in descending order of frequency. We used chi-square test to compare baseline demographic characteristics between the CLE and SLE cohorts. We used multivariable logistic and linear regression analysis, adjusting for gender, age, Charlson comorbidity index score (CCI), insurance status, and income for categorical and continuous hospital outcomes respectively between both cohorts.

Results: About 142 million hospitalizations were included in the combined NIS databases, out of which the SLE cohort contained 130,475 hospitalizations (0.09%) while the CLE cohort contained 62,435 hospitalizations (0.04%). The CLE cohort was older, had fewer females, lower inpatient mortality, shorter hospital length of stay (LOS), less total hospital charges, less CCI, more whites, and fewer racial minorities compared to the SLE cohorts (Table 1). The CLE cohort had more cardiovascular (CV) risk factors such as dyslipidemia, prior myocardial infarction, hypertension, peripheral vascular disease, type 2 diabetes, obesity, and smoking compared to the SLE cohort. The most common principal diagnosis category of hospitalizations of patients with CLE was CV (Figure 1), while the most common specific principal diagnosis for these patients was sepsis (Table 2).

Conclusion: Hospitalized CLE patients differ significantly from SLE patients in terms of socio-demographics, comorbidities, and hospital outcomes. Management of comorbidities (such as CV), and measures to prevent and early detection of infections in the outpatient are necessary in reducing hospitalizations of these patients.

Supporting image 1

Table 1: Baseline characteristics and hospital outcomes of hospitalizations of patients with Cutaneous lupus erythematosus and Systemic lupus erythematosus with organ involvement

Abbreviations
CLE: Cutaneous lupus erythematosus, SLE: Systemic lupus erythematosus with organ or systemic involvement, MI: Myocardial infarction, PCI: percutaneous coronary intervention, CABG: Coronary artery bypass graft, COPD: Chronic obstructive pulmonary disease, DM: Diabetes Mellitus, CHF: Chronic congestive heart failure, CKD: Chronic kidney disease, O2: oxygen, A. Fib: Atrial fibrillation, median household income: median household income for patient’s Zip code, Co-morbidities: Secondary diagnosis present at admission or developed during hospitalization, aOR, CI: 95% CI: 95% confidence interval

Supporting image 2

Table 2: ICD_10 code categories and specific principal discharge diagnosis for cutaneous lupus erythematosus hospitalizations *

* Hospitalizations for patients with principal or secondary diagnosis of cutaneous lupus erythematosus. COPD: Chronic obstructive pulmonary disease. CKD: Chronic kidney disease, HF: Heart failure

Supporting image 3

Figure 1: Pareto chart of ICD_10 code categories in descending order of frequency for hospitalization of patients with Cutaneous Lupus Erythematosus. Line on the secondary axis plots the cumulative percentages of each ICD_10 code categories.

Abbreviations: Hema/Onc: Neoplasms & diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, Endo: Endocrine, nutritional and metabolic diseases, Psych: Mental, behavioral and neurodevelopmental disorders, Neuro: Diseases of the nervous system, CVS: Diseases of the circulatory system, Respiratory: Diseases of the respiratory system, GI: Diseases of the digestive system, Rheum: Diseases of the musculoskeletal system and connective tissue, GU: Diseases of the genitourinary system, others: Symptoms, signs, and abnormal clinical laboratory findings, not elsewhere classified, Health services: Factors influencing health status and contact with health services


Disclosures: E. Edigin, None; A. Trang, None; C. Osuorji, None; C. Hino, None; S. Anighoro, None; P. Eseaton, None; N. Chukwu, None; O. Aihie, None; A. Manadan, None; v. Sandhu, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Edigin E, Trang A, Osuorji C, Hino C, Anighoro S, Eseaton P, Chukwu N, Aihie O, Manadan A, Sandhu v. Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/analysis-of-cutaneous-lupus-hospitalizations-a-united-states-national-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-cutaneous-lupus-hospitalizations-a-united-states-national-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology